

HE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Reed et al.

Confirmation No.: 5470

Application No.: 10/823,253

Group Art Unit: 1644

Filed: April 12, 2004

Examiner: Skelding, Zachary

For: RECOMBINANT IL-9 ANTIBODIES AND USES THEREOF

Attorney Docket No.: IL402US

## INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR §1.56**

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form(s) PTO/SB/08, a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 C.F.R. §§ 1.97-1.98.

## TIMING OF THE DISCLOSURE

(1) The listed documents are being submitted in compliance with 37 C.F.R. §1.97(d):

Applicants respectfully submit, as provided under 37 C.F.R. §1.97(e)(1), that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Applicants also authorize the Commissioner to charge the fee set forth in § 1.17(p), and any other fee necessary, for consideration of each item of information disclosed in the information disclosure statement to Deposit Account No. 500479.

(2) Applicants further respectfully submit that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement.

10/10/2006 JADDO1

00000177 500479

10823253

01 FC:1866

180.00 DA

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Respectfully submitted,

Michelle Holmes-Son

Registration No. 47,660

Date: October 6, 2006

MEDIMMUNE, INC.

Customer Number: 36577

Telephone:

(301) 398-5765

Facsimile:

(301) 398-9306



PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduc ction Act of 1995, no persons are required to res

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/823,253		
Filing Date	April 12, 2004		
First Named Inventor	REED, Jennifer		
Art Unit	1644		
Examiner Name	SKELDING, Zachary		
Attorney Docket Number	r IL402US		

Examiner	Cite	Document Number	U. S. PATENT D	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	Cite No.1	Document (varioe)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant
		Number-Kind Code <sup>2 (# known)</sup>		, pp. 200 200 200 200 200 200 200 200 200 20	Figures Appear
		US-			
	<u> </u>	US-			
		US-			
	<del> </del>	US-			

	-	FOREIG	GN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ <sup>6</sup>
	B1	WO-2003-086458- A1	10-23-2003			
	L					Щ

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduct ersons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/823,253 INFORMATION DISCLOSURE Filing Date April 12, 2004 STATEMENT BY APPLICANT **First Named Inventor** REED, Jennifer Art Unit 1644 (Use as many sheets as necessary) **Examiner Name** SKELDING, Zachary Attorney Docket Number Sheet 2 **IL402US** of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials* Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number(s), publisher, city and/or country where published.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Kung et al., 2001, "Effect of Anti-mIL-9 Antibody on the Development of Pulmonary Inflammation and Airway" Am. J. Respir. Cell Mol Biol. Vol 25: 600-605.	
		Gruss et al., 1992, "Interleukin 9 Is Expressed By Primrary and Cultured Hodgkin and Reed-Sternberg Cells", Cancer Res. 52: 1026-1031.	
		Temann et al. 1998, "Expression of Interleukin 9 in the Lungs of Transgenic Mice Causes Airway" J. of Experimental Medicine 188(7):1307-1320.	
-		Abdelilah et al., 2001, "Functional Expression of IL-9 Receptor by Human Neutrophils from Asthmatic"Am. Assoc. of Immunologists pp. 2768-2774.	
<del></del>			

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.